Tag: immunoglobulins market analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Immunoglobulins Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The immunoglobulins market has seen rapid expansion over recent years. This market is projected to expand from $20.32 billion in 2025 to $22.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. Factors contributing to this historical growth include the rising incidence of immunodeficiency diseases, a surge in autoimmune disorder cases, enhancements in hospital infrastructure, progress in plasma fractionation technologies, and increasing recognition of antibody-based therapies.

The immunoglobulins market is projected to experience substantial expansion in the coming years. It is anticipated to reach a valuation of $34.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This anticipated growth throughout the forecast period stems from factors such as progress in personalized medicine, the creation of new monoclonal antibodies, an increase in home-based subcutaneous treatments, the proliferation of biotechnology and research facilities, and rising government backing for immunotherapy initiatives. Key trends for the forecast duration encompass personalized immunoglobulin therapies, a growing embrace of subcutaneous delivery techniques, heightened demand for IVIG in autoimmune conditions, the broadening of treatments for rare immunodeficiencies, and an increase in monoclonal antibody research.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=53073366&type=smp&name=Immunoglobulins%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immunoglobulins Market Growth Momentum: What Factors Are Shaping Demand?

The growth of the hyperphosphatemia treatment market is anticipated to be propelled by increasing healthcare expenditure. Hyperphosphatemia treatments involve therapies and medications designed to lower elevated phosphate levels in the blood, a common issue for patients with chronic kidney disease and other related conditions. Higher healthcare spending facilitates broader access to these treatments, supports the research and development of advanced therapies, and improves patient management strategies. For example, in November 2023, the Canadian Institute for Health Information, based in Canada, projected that total health spending in Canada would reach $344 billion in 2023, equivalent to $8,740 per person. This indicates a 2.8% increase compared to 2022, significantly higher than the 1.5% growth in health spending observed in 2022, highlighting a substantial resurgence in healthcare investment. Therefore, the expanding healthcare expenditure is a primary driver for the hyperphosphatemia treatment market’s growth.

Immunoglobulins Market Segmentation: How Does The Market Break Down By Category?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

Immunoglobulins Market Trends Redefining Industry Growth

Leading firms within the immunoglobulins market are innovating products like intravenous immunoglobulins to expand their customer reach, boost sales, and enhance revenue. For example, in September 2024, GC Biopharma, a biotechnology company based in South Korea, introduced ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid into the U.S. market. This product is intended for managing primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now accessible to patients via specialty pharmacies. This launch holds considerable importance because the U.S. constitutes the world’s largest immunoglobulin market, estimated at approximately $11.6 billion. GC Biopharma projects ALYGLO sales of $50 million in its initial year, with ambitions to elevate this sum to $300 million by 2028. Their ambitious growth plan includes collaborations with prominent U.S. pharmacy benefit managers and specialty pharmacies, which are vital for the efficient distribution of immunoglobulin products.

Immunoglobulins Market Competitive Overview And Top Companies

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

View The Full Immunoglobulins Market Report:

https://thebusinessresearchcompany.com/report/immunoglobulins-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immunoglobulins Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Immunoglobulins Market Growth From $22.51 Billion In 2026 To $34.52 Billion By 2030 At A CAGR Of 11.3%

The immunoglobulins market has seen swift expansion in recent times. Valued at $20.32 billion in 2025, it is projected to reach $22.52 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. This past growth has been fueled by a rising incidence of immunodeficiency conditions, a growing number of autoimmune disease cases, improvements in hospital facilities, advances in plasma fractionation technology, and heightened awareness regarding antibody-based treatments.

The market for immunoglobulins is projected to experience rapid expansion over the coming years, reaching a value of $34.52 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.3%. This anticipated growth during the forecast period is driven by progress in personalized medicine, the creation of innovative monoclonal antibodies, a rise in home-based subcutaneous treatments, the proliferation of biotechnology and research facilities, and enhanced government backing for immunotherapy programs. Key developments shaping the market outlook include the shift toward tailored immunoglobulin therapies, a greater preference for subcutaneous administration methods, heightened demand for intravenous immunoglobulin (IVIG) in autoimmune conditions, the broadening of treatment options for rare immunodeficiency disorders, and progress in monoclonal antibody research.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Immunoglobulins Market Demand Drivers Creating New Revenue Opportunities

The continued rise in healthcare spending is anticipated to drive expansion within the hyperphosphatemia treatment market in the coming period. This condition, which involves managing therapies and medications designed to lower excessive phosphate levels in the bloodstream—often found in individuals with chronic kidney disease or similar disorders—benefits directly from greater financial resources allocated to medical care. Enhanced funding enables wider availability of these interventions, fuels progress in developing more sophisticated treatment options, and refines approaches to patient care. To illustrate, data from the Canadian Institute for Health Information, released in November 2023, shows that Canada’s total annual health expenditure is forecast to hit $344 billion, or roughly $8,740 per person, by the end of that year. That figure represents a 2.8% uptick from 2022, a year which recorded a notably slower growth rate of just 1.5%, signaling a clear resurgence in investment within the health sector. As a result, this upward trend in spending is fueling the momentum behind the hyperphosphatemia treatment market’s growth.

Immunoglobulins Market Segment Breakdown: Which Categories Generate The Most Revenue?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

Immunoglobulins Market Trends Driving Strategic Industry Expansion

Key players within the immunoglobulins sector are concentrating on creating advanced products, including intravenous immunoglobulins, with the goal of reaching a broader customer base, driving higher sales volumes, and boosting overall revenue. A notable example occurred in September 2024 when GC Biopharma, a biotechnology firm headquartered in South Korea, introduced ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid into the U.S. market. This product is intended for the management of primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now accessible to patients via specialty pharmacy channels. This launch holds considerable importance because the United States represents the world’s largest marketplace for immunoglobulins, with an estimated value of around $11.6 billion. GC Biopharma has set a target to generate $50 million in sales from ALYGLO during its initial year, and it aspires to escalate this figure to $300 million by 2028. To realize this ambitious growth plan, the company is forging alliances with major U.S. pharmacy benefit managers and specialty pharmacies, entities that play a vital role in the efficient distribution of immunoglobulin therapies.

Immunoglobulins Market Key Players And Strategic Industry Positioning

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Access The Complete Immunoglobulins Market Report:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Immunoglobulins Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Immunoglobulins Market By 2030?

The immunoglobulins market size has experienced swift expansion over recent years. It is anticipated to grow from $20.32 billion in 2025 to $22.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historic period can be attributed to the increasing prevalence of immunodeficiency diseases, a rise in autoimmune disorder cases, enhancements in hospital infrastructure, technological progress in plasma fractionation, and a broader understanding of antibody therapies.

The immunoglobulins market size is expected to experience substantial growth in the upcoming years. It is projected to reach $34.52 billion in 2030, with a compound annual growth rate (CAGR) of 11.3%. The expansion within this forecast period can be attributed to advancements in personalized medicine, the emergence of novel monoclonal antibodies, an increase in home-based subcutaneous therapies, the broadening of biotechnology and research centers, and greater government backing for immunotherapy programs. Significant trends foreseen for this period include personalized immunoglobulin therapy, a rising adoption of subcutaneous delivery methods, increased demand for IVIG in autoimmune disorders, the expansion of treatments for rare immunodeficiencies, and heightened research in monoclonal antibodies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

Which Core Factors Are Supporting The Expansion Of The Immunoglobulins Market?

The hyperphosphatemia treatment market is anticipated to grow, driven by rising healthcare expenditure. Treatment for hyperphosphatemia involves therapies and medications focused on reducing high phosphate levels in the blood, a common occurrence in individuals with chronic kidney disease and similar conditions. Increased spending on healthcare allows for wider availability of such treatments, supports the research and development of advanced therapies, and enhances strategies for patient management. For example, in November 2023, the Canadian Institute for Health Information, a Canada-based organization, projected that total health spending in Canada would reach $344 billion in 2023, amounting to $8,740 per person. This represents a 2.8% increase compared to 2022, which experienced only a 1.5% growth in health spending, signaling a notable rebound in healthcare investment. Consequently, the increasing healthcare expenditure is propelling the expansion of the hyperphosphatemia treatment market.

How Is The Immunoglobulins Market Distributed Across Key Segments?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

Which Trends Are Contributing To Changes In The Immunoglobulins Market?

Leading firms within the immunoglobulins market are introducing advanced offerings like intravenous immunoglobulins, aiming to attract broader customer segments, boost sales, and enhance income. As an illustration, GC Biopharma, a biotechnology company from South Korea, unveiled ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market in September 2024. This product is designed for treating primary humoral immunodeficiency (PI) in adults aged 17 and above and is currently accessible to patients via specialty pharmacies. This introduction holds considerable importance because the U.S. constitutes the world’s largest immunoglobulin market, estimated at approximately $11.6 billion. GC Biopharma intends to reach $50 million in ALYGLO sales during its inaugural year, with projections to escalate this sum to $300 million by 2028. This ambitious expansion strategy necessitates collaborations with prominent U.S. pharmacy benefit managers and specialty pharmacies, partnerships vital for the efficient distribution of immunoglobulin products.

Who Are The Companies Shaping The Immunoglobulins Market Landscape?

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Access The Complete Immunoglobulins Market Report:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Area Represents The Largest Portion Of The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immunoglobulins Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

Browse Through More Reports Similar to the Global Immunoglobulins Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Hyperimmune Globulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Immunoglobulins Market Progress Between 2026 And 2030?

The immunoglobulins market has experienced significant expansion in recent years. Forecasts suggest it will grow from $20.32 billion in 2025 to $22.52 billion in 2026, with a compound annual growth rate (CAGR) of 10.8%. This historical growth can be attributed to the increasing prevalence of immunodeficiency diseases, a rise in autoimmune disorder cases, improvements in hospital infrastructure, technological advancements in plasma fractionation, and expanding awareness regarding antibody therapies.

The immunoglobulins market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $34.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This projected growth stems from several factors, including breakthroughs in personalized medicine, the creation of innovative monoclonal antibodies, a rise in home-based subcutaneous treatments, the broadening of biotechnology and research facilities, and increasing governmental backing for immunotherapy initiatives. Key developments expected during this period involve tailored immunoglobulin therapy, a greater preference for subcutaneous administration, an increasing need for IVIG in treating autoimmune conditions, the wider availability of treatments for rare immunodeficiency disorders, and an escalation in monoclonal antibody research.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

What Major Factors Are Driving The Immunoglobulins Market Forward?

The hyperphosphatemia treatment market is anticipated to expand due to increasing healthcare expenditure. These treatments, which target the reduction of elevated phosphate levels in the blood often seen in individuals with chronic kidney disease and similar conditions, benefit significantly from higher healthcare spending. Such increased investment facilitates wider availability of these therapies, fosters research and development for new treatments, and enhances overall patient management approaches. As an illustration, the Canadian Institute for Health Information reported in November 2023 that Canada’s total health spending for 2023 is estimated to reach $344 billion, amounting to $8,740 per person. This represents a 2.8% rise from 2022, a year that experienced only 1.5% growth in health spending, signaling a substantial recovery in healthcare investment. Consequently, the escalating healthcare expenditure is a key factor driving the expansion of the hyperphosphatemia treatment market.

How Is The Immunoglobulins Market Segmented Across Different Segment Categories?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

What Trends Are Affecting The Direction Of The Immunoglobulins Market?

Companies operating within the immunoglobulins market are actively developing novel products, such as intravenous immunoglobulins, aimed at expanding their customer base, increasing sales, and boosting revenue. Illustratively, in September 2024, GC Biopharma, a biotechnology firm from South Korea, introduced ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid into the U.S. market. This product is designed for treating primary humoral immunodeficiency (PI) in adults aged 17 and above and is now accessible to patients via specialty pharmacies. The launch holds considerable importance given that the U.S. represents the largest immunoglobulin market globally, with an estimated value of $11.6 billion. GC Biopharma projects ALYGLO sales to reach $50 million in its inaugural year, with aspirations to elevate this figure to $300 million by 2028. This ambitious growth plan relies on forming alliances with prominent U.S. pharmacy benefit managers and specialty pharmacies, which are vital for the efficient distribution of immunoglobulin products.

Which Organizations Play A Role In The Immunoglobulins Market Landscape?

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Get The Full Immunoglobulins Market Report:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Region Is The Largest In The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Immunoglobulins Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Browse Through More Reports Similar to the Global Immunoglobulins Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Hyperimmune Globulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Immunoglobulins Market Expected To Change Between 2026 And 2030?

The immunoglobulins market has experienced significant growth in recent years. It is projected to expand from $20.32 billion in 2025 to $22.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. This historical expansion can be attributed to factors such as the rising prevalence of immunodeficiency diseases, an increasing number of autoimmune disorder cases, improvements in hospital infrastructure, technological advancements in plasma fractionation, and broadening awareness about antibody therapies.

The immunoglobulins market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $34.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.3%. This anticipated expansion throughout the forecast period stems from factors such as progress in personalized medicine, the creation of innovative monoclonal antibodies, a rise in home-based subcutaneous treatments, the broadening of biotechnology and research facilities, and increasing governmental backing for immunotherapy initiatives. Significant developments expected during this forecast span encompass individualized immunoglobulin therapies, a growing preference for subcutaneous delivery techniques, an escalating need for ivig in the treatment of autoimmune conditions, the broadening of available treatments for rare immunodeficiencies, and an increase in research focused on monoclonal antibodies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

What Drivers Are Expected To Influence The Immunoglobulins Market During The Forecast Period?

The anticipated increase in healthcare spending is expected to propel the growth of the hyperphosphatemia treatment market going forward. Hyperphosphatemia treatment involves therapies and medications aimed at reducing elevated phosphate levels in the blood, which commonly occur in patients with chronic kidney disease and other related conditions. Greater healthcare spending allows for broader access to such treatments, supports research and development of advanced therapies, and improves patient management strategies. For instance, in November 2023, the Canadian Institute for Health Information projected Canada’s total health spending for 2023 to reach $344 billion, equating to $8,740 per person. This represents a 2.8% increase compared to 2022, which had only a 1.5% growth in health spending, indicating a notable rebound in healthcare investment. Therefore, the increasing healthcare expenditure is a key driver for the growth of the hyperphosphatemia treatment market.

How Is The Immunoglobulins Market Structured Across Different Segments?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

Which Trends Are Shaping The Future Of The Immunoglobulins Market?

Leading companies within the immunoglobulins market are focused on developing innovative offerings, such as intravenous immunoglobulins, to expand their customer base, boost sales, and enhance revenue. For instance, in September 2024, GC Biopharma, a biotechnology company based in South Korea, launched ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market. This product targets the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now accessible to patients through specialty pharmacies. This launch is particularly significant given that the U.S. represents the largest immunoglobulin market globally, with an approximate valuation of $11.6 billion. GC Biopharma aims to generate $50 million in sales for ALYGLO in its inaugural year, with projections to increase this figure to $300 million by 2028. This ambitious growth strategy involves forming partnerships with major U.S. pharmacy benefit managers and specialty pharmacies, which are essential for the effective distribution of immunoglobulin products.

Which Major Players Dominate The Immunoglobulins Market?

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Read the full immunoglobulins market report here:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Region Is Forecast To Lead The Immunoglobulins Market In Terms Of Market Size?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Immunoglobulins Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

Browse Through More Reports Similar to the Global Immunoglobulins Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Hyperimmune Globulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the immunoglobulins market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Immunoglobulins Market between 2026 and 2030?

The immunoglobulins market has seen substantial expansion in recent years. This market is set to expand from $20.32 billion in 2025 to $22.52 billion by 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The historical development of the market is primarily due to the increasing occurrence of immunodeficiency diseases, a rise in autoimmune disorder cases, enhancements in hospital infrastructure, innovations in plasma fractionation, and a broader understanding of antibody therapies.

The immunoglobulins market is anticipated to experience significant expansion in the coming years, with its size projected to reach $34.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.3%. This projected growth can be attributed to several factors, including advancements in personalized medicine, the development of novel monoclonal antibodies, an increase in home-based subcutaneous therapies, the expansion of biotechnology and research centers, and growing government support for immunotherapy programs. Furthermore, major trends identified for the forecast period involve personalized immunoglobulin therapy, the increasing adoption of subcutaneous delivery methods, a rising demand for IVIG in autoimmune disorders, the expansion of treatments for rare immunodeficiency conditions, and an overall growth in monoclonal antibody research.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Immunoglobulins Market?

The hyperphosphatemia treatment market is poised for growth, primarily fueled by increasing healthcare expenditure. Hyperphosphatemia treatment encompasses therapies and drugs designed to lower high blood phosphate levels, frequently observed in individuals with chronic kidney disease and associated ailments. Enhanced spending in healthcare facilitates wider availability of these treatments, fosters research and development of innovative therapies, and refines patient care approaches. A pertinent example is Canada’s projected total health spending, which, according to the Canadian Institute for Health Information in November 2023, is set to hit $344 billion in 2023, translating to $8,740 per individual. This represents a 2.8% rise from 2022, contrasting with the mere 1.5% growth in 2022, thereby signaling a significant resurgence in healthcare investment. Consequently, the expansion of healthcare expenditure is driving the growth of the hyperphosphatemia treatment market.

What Segments Are Included Within The Immunoglobulins Market?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

Which Innovation Trends Are Advancing Developments Within The Immunoglobulins Market?

Leading companies within the immunoglobulins market are innovating products such as intravenous immunoglobulins to cater to wider customer bases, generate higher sales, and increase revenue. For instance, in September 2024, GC Biopharma, a biotechnology company based in South Korea, launched ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market. This product targets the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now available to patients through specialty pharmacies. This introduction is significant as the U.S. represents the globe’s largest immunoglobulin market, valued at approximately $11.6 billion. GC Biopharma projects ALYGLO sales of $50 million in its first year, aiming to raise this figure to $300 million by 2028. This ambitious growth strategy involves forming partnerships with key U.S. pharmacy benefit managers and specialty pharmacies, essential for effective distribution of immunoglobulin products.

Who Are The Primary Competitors In The Global Immunoglobulins Market?

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Immunoglobulins Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

Browse Through More Reports Similar to the Global Immunoglobulins Market 2026, By The Business Research Company

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Hyperimmune Globulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the immunoglobulins market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Immunoglobulins Market Now And By 2029?

The immunoglobulins market has shown significant expansion in recent years. Its value is anticipated to rise from $18.85 billion in 2024 to $20.32 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be linked to a higher incidence of immunodeficiency disorders, an expanding older population, increased utilization of immunoglobulins in hospital settings, beneficial government reimbursement programs, and the rising occurrence of chronic and autoimmune diseases.

The immunoglobulins market is anticipated to experience substantial growth in the near future. By 2029, its value is forecast to reach $30.89 billion, exhibiting a compound annual growth rate (CAGR) of 11.0%. This anticipated growth is driven by factors such as greater investment in advanced technology development, heightened awareness of immunodeficiency therapies, an increasing preference among medical professionals for these treatments, the emergence of more markets, and the broadening of applications in areas like sports and fitness. Key trends during this period are expected to encompass the creation of wearable and smart compression devices, tailored compression therapy solutions, the incorporation of compression therapy into wound care management, a focus on patient comfort and adherence in compression therapy, and partnerships between manufacturers and healthcare providers to enhance patient results.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

Which Long-Term Drivers Are Expected To Sustain The Immunoglobulins Market?

The expanding geriatric population is a primary catalyst for the growth of the immunoglobulins market. Elderly individuals are highly susceptible to infectious diseases and auto-immune conditions. An immunoglobulin test measures the body’s capacity to produce antibodies that provide defense against bacteria, viruses, and allergies. For example, in October 2022, a report from the World Health Organization (WHO), a Switzerland-based agency dedicated to international public health, indicated that by 2030, one in six people worldwide is projected to be 60 or older. This trend continues, with 2.1 billion people globally expected to be 60 years old or older by 2050. Therefore, the rising geriatric population is set to boost the demand for the immunoglobulins market over the forecast period.

How Is The Immunoglobulins Market Classified By Different Segments?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD.

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

What Current And Upcoming Trends Are Shaping The Immunoglobulins Market?

Leading companies in the immunoglobulins market are developing innovative products like intravenous immunoglobulins to attract larger customer bases, boost sales, and enhance revenue. For instance, in September 2024, GC Biopharma, a South Korean-based biotechnology company, launched ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market, intended for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This product is now accessible to patients via specialty pharmacies. The introduction is noteworthy because the U.S. represents the largest global immunoglobulin market, with an approximate valuation of $11.6 billion. GC Biopharma targets $50 million in sales for ALYGLO in its initial year, with projections to increase this amount to $300 million by 2028. This extensive growth strategy involves collaborations with major U.S. pharmacy benefit managers and specialty pharmacies, which are essential for the efficient distribution of immunoglobulin products.

Who Are The Primary Market Leaders In The Immunoglobulins Market?

Major companies operating in the immunoglobulins market include Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

Browse Through More Reports Similar to the Global Immunoglobulins Market 2025, By The Business Research Company

Orphan Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/orphan-drug-global-market-report

Drug Delivery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Immunoglobulins Market Expected To Expand Between 2025 And 2029?

The immunoglobulins market size has experienced significant expansion in recent years. It is anticipated to increase from $18.85 billion in 2024 to $20.32 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.8%. This historical growth can be attributed to several factors, including the rising prevalence of immunodeficiency disorders, an expanding geriatric population, the increasing adoption of immunoglobulins within hospitals, favorable government reimbursement plans, and the growing incidence of chronic and autoimmune diseases.

The immunoglobulins market size is anticipated to experience rapid expansion in the coming years, projected to reach $30.89 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is attributable to increasing investment in developing advanced technologies, growing awareness regarding immunodeficiency therapies, a rising preference for these therapies among physicians, an expanding number of emerging markets, and the broadening of applications in sports and fitness. Major trends expected in this period encompass the development of wearable and smart compression devices, the customization of compression therapy solutions, the integration of compression therapy into wound care management, an increased emphasis on patient comfort and compliance in compression therapy, and collaborations between manufacturers and healthcare providers to enhance patient outcomes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

Which Drivers Are Impacting The Immunoglobulins Market?

The rising number of elderly individuals fuels the expansion of the immunoglobulins market. Older adults face a significant susceptibility to infectious and autoimmune conditions. An immunoglobulin test assesses the body’s capacity to generate antibodies, which defend against bacteria, viruses, and allergic reactions. For example, a report released by the World Health Organization (WHO), the Switzerland-based international public health agency, indicated in October 2022 that globally, one in six individuals is projected to be 60 or older by 2030. Furthermore, by 2050, the global population aged 60 years or older is anticipated to reach 2.1 billion. Consequently, the growing elderly demographic is projected to boost the demand within the immunoglobulins market throughout the forecast period.

What Are The Major Segments Identified In The Immunoglobulins Market?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD.

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

What Are The Latest Industry Trends Transforming The Immunoglobulins Market?

Companies operating in the immunoglobulins market are actively developing innovative solutions like intravenous immunoglobulins to cater to broader customer bases, drive increased sales, and boost revenue. For instance, in September 2024, the South Korean biotechnology company GC Biopharma introduced ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid into the U.S. market. This product is intended for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older and is now available to patients through specialty pharmacies. This introduction is notable because the U.S. represents the globe’s largest immunoglobulin market, valued at approximately $11.6 billion. GC Biopharma’s objective is to achieve $50 million in ALYGLO sales during its first year, with plans to elevate this figure to $300 million by 2028. This ambitious growth strategy encompasses partnerships with major U.S. pharmacy benefit managers and specialty pharmacies, which are essential for the effective distribution of immunoglobulin products.

Which Key Players Are Driving Competition In The Immunoglobulins Market?

Major companies operating in the immunoglobulins market include Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Region Currently Holds The Largest Share Of The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Immunoglobulins Market Report:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

Browse Through More Reports Similar to the Global Immunoglobulins Market 2025, By The Business Research Company

Orphan Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/orphan-drug-global-market-report

Drug Delivery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Immunoglobulins Market?

The market size for immunoglobulins has experienced robust growth in the recent past. Projections show an increase from $18.85 billion in 2024 to $20.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.8%. The substantial growth in the previous period is linked to the rising occurrence of immunodeficiency disorders, an expanding elderly population, the increasing use of immunoglobulins in hospital settings, beneficial government reimbursement programs, and an increase in chronic and autoimmune diseases.

In the coming years, the immunoglobulins market size is projected to observe significant growth, escalating to “$30.89 billion in 2029 with a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is primarily due to the surge in investment towards innovative technology development, heightened awareness surrounding immunodeficiency treatments, physicians’ increasing reliance on immunodeficiency treatments, the rise of new markets and widened applications in sports and fitness. Leading trends to watch for during the forecast period consist of the creation of wearable and smart compression devices, personalization of compression therapy solutions, compression therapy integration in wound care management, a focus on patient comfort and compliance in compression therapy, and collaboration between manufacturers and healthcare providers to enhance patient outcomes.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

What Are The Primary Factors Supporting The Immunoglobulins Market Expansion?

The escalation in the elderly population is driving the expansion of the immunoglobulins market. This age demographic is exceptionally susceptible to infectious and auto-immune diseases. The test for immunoglobulin assesses the capacity of the body to generate antibodies for defense against bacteria, viruses, and allergies. As an example, a report from the World Health Organization (WHO), a Swiss-based entity accountable for global public health, predicted in October 2022 that by 2030, one out of every six individuals around the world will be 60 or above. The prediction extends to 2050, when there will be 2.1 billion people globally aged 60 or more. Accordingly, the demographic growth of the older population is forecasted to amplify demand in the immunoglobulins market.

Which Segments Define The Structure Of The Immunoglobulins Market?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD.

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

What Strategic Shifts And Innovations Are Influencing The Immunoglobulins Market?

Key businesses in the immunoglobulins sector are focusing on innovation and new product creation, like intravenous immunoglobulins, in an attempt to reach a larger audience, boost sales, and elevate earnings. In September 2024, for example, GC Biopharma, a biotech firm based in South Korea, introduced their product ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid to the U.S. market. This product aims to treat primary humoral immunodeficiency (PI) in adults who are 17 years or older and can be accessed via specialty pharmacies. The introduction is pivotal since the U.S. has the biggest immunoglobulin market worldwide, standing at an estimated value of $11.6 billion. GC Biopharma has set its sights on reaching $50 million in ALYGLO sales in its inaugural year, with a goal to elevate this number to $300 million by 2028. Their aggressive expansion plan includes collaborations with significant U.S. pharmacy benefit managers and specialty pharmacies, which are essential for the effective distribution of immunoglobulin products.

Who Are The Primary Market Leaders In The Immunoglobulins Market?

Major companies operating in the immunoglobulins market include Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

What Regional Factors Are Accelerating Growth In The Immunoglobulins Market?

North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Immunoglobulins Industry?

The market for immunoglobulins has seen robust growth in recent times. The market value is anticipated to increase from $18.85 billion in 2024 to $20.32 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.8%. Factors such as the rising numbers of immunodeficiency disorders, an expanding elderly population, increased usage of immunoglobulins in hospital settings, beneficial government reimbursement schemes, and an escalating prevalence of chronic and autoimmune diseases have all contributed to the growth during the historical period.

The market for immunoglobulins is forecasted to experience a significant increase in the coming years, with its size projected to reach “$30.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.0%. The growth predicted for this period can be associated with the rising investment in the development of advanced technologies, heightened understanding and awareness of immunodeficiency therapies, growing preference among medical professionals for these therapies, the rise of emerging markets, and the widening of its application in sports and fitness. Major emerging trends expected in this period include the advancement of wearable and smart compression devices, personalization of compression therapy solutions, incorporation of compression therapy in wound management, focus on patient comfort and compliance during compression therapy, and partnerships between manufacturers and health service providers for enhanced patient outcomes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5284&type=smp

What Forces Are Driving The Growth Of The Immunoglobulins Industry?

The immunoglobulins market’s growth is being propelled by the rise in the elderly population. Seniors have a higher likelihood of contracting infectious and auto-immune diseases. Immunoglobulin tests reveal the capacity of one’s immune system to create antibodies that defend against bacteria, viruses, and allergies. For instance, a 2022 report from the World Health Organization (WHO), which oversees global public health from their base in Switzerland, projected that by 2030, one in six people globally will be 60 or older. By 2050, the global population of individuals aged 60 or older is anticipated to reach 2.1 billion. Therefore, the rise in the number of elderly individuals is predicted to spur demand in the immunoglobulins market over the forecast period.

What Is The Overview Of Market Segmentation In The Immunoglobulins Industry?

The immunoglobulins market covered in this report is segmented –

1) By Product: IGG, IGA, IGM, IGE, IGD.

2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications

Subsegments:

1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin)

2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA

3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM

4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE

5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGD

What Long-Term Trends Are Likely To Affect The Immunoglobulins Market?

Leading companies in the immunoglobulins market are creating groundbreaking products like intravenous immunoglobulins for greater customer reach, increased sales and higher revenue. In September 2024, for example, GC Biopharma, a biotech company based in South Korea, introduced ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market, aiming to treat the primary humoral immunodeficiency (PI) in adults aged 17 years and older. Their offer now reaches the patients through speciality pharmacies. It’s a meaningful step as the U.S. is the largest immunoglobulin market in the world, estimated at about $11.6 billion. GC Biopharma has set a target of $50 million in ALYGLO sales in its debut year, with an objective to raise this amount to $300 million by 2028. This aggressive growth plan includes alliances with large U.S. pharmacy benefit managers and specialised pharmacies that are essential for effective distribution of immunoglobulin goods.

Who Are The Primary Players Operating Across The Global Immunoglobulins Market?

Major companies operating in the immunoglobulins market include Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Which Region Offers The Most Growth Potential For The Immunoglobulins Market Through 2029?

North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=5284&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model